Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group Short title: t-AML/MDS after Hodgkin lymphoma

Therapy-related acute myeloid leukemia and myelodysplastic syndromes (tAML/MDS) represent severe late effects in patients treated for Hodgkin lymphoma (HL). As more recent data are scarce, we retrospectively analyzed incidence, outcome and risk factors for the development of t-AML/MDS after HL. A total of 11952 patients treated for newly diagnosed HL within GHSG trials between 1993 and 2009 were considered. At a median follow-up of 72 months, t-AML/MDS was diagnosed in 106/11952 patients (0.9%). Median time from HL treatment to tAML/MDS was 31 months. The median age of patients with t-AML/MDS was higher than in the whole patient group (43 vs 34 years, p<0.0001). Patients who received four or more cycles of BEACOPPescalated had an increased risk to develop t-AML/MDS when compared with patients treated with less than four cycles of BEACOPPescalated or no BEACOPP chemotherapy (1.7% vs 0.7% vs 0.3%, p<0.0001). The median OS for all t-AML/MDS patients was 7.2 months. However, t-AML/MDS patients proceeding to allogeneic stem cell transplantation (aSCT) had a significantly better outcome with a median OS not reached after a median follow-up of 41 months (p<0.001). For personal use only. on February 3, 2017. by guest www.bloodjournal.org From